Cobicistat is a PK (pharmacokinetic) booster that is used to increase levels of some other HIV meds. It is similar to ritonavir in the way it boosts drugs. Unlike ritonavir, cobicistat does not directly work against HIV.
- Cobicistat was approved in Europe in September 2013
- It can be used to boost either atazanavir (300 mg once-daily dose) or darunavir (800 mg once-daily dose).
- It is not approved to boost other protease inhibitors.
- Cobicistat is dosed at 1 x 150 mg tablet once-daily.
- Cobicistat can interact with a wide range of other HIV drugs and non-HIV drugs, including supplements and over-the-counter medicines. Please make sure that your HIV doctor and pharmacist know about any other medicines, drugs or supplements that you take.
- Cobicistat is coformulated with darunavir in a single tablet called Prezcobix.
The European patient information and detailed Product Information for cobicistat (Tybost) will be available at this link at the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.